Citation Impact
Citing Papers
Systemic Targeting of CpG-ODN to the Tumor Microenvironment with Anti–neu-CpG Hybrid Molecule and T Regulatory Cell Depletion Induces Memory Responses in BALB-neuT Tolerant Mice
2008 StandoutNobel
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
2009 Standout
From traditional Chinese medicine to rational cancer therapy
2007 Standout
A newly discovered class of human hematopoietic cells with SCID-repopulating activity
1998
Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors
2012
Curcumin, the Golden Spice From Indian Saffron, Is a Chemosensitizer and Radiosensitizer for Tumors and Chemoprotector and Radioprotector for Normal Organs
2010 Standout
Homoharringtonine and omacetaxine for myeloid hematological malignancies
2014
Features of the dendritic cell lineage
2010 StandoutNobel
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
2002 Standout
Effect of Imatinib Mesylate on Chronic Myelogenous Leukemia Hematopoietic Progenitor Cells
2003
Natural products: An evolving role in future drug discovery
2011 Standout
Mechanisms and insights into drug resistance in cancer
2013
Cytokine regulation of endothelial cell function: from molecular level to the bedside
1997
Results of triple therapy with interferon‐alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase
2003
Viruses in human cancers
1999 StandoutNobel
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
2001 Standout
Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts
2004 StandoutNature
Immune response to green fluorescent protein: implications for gene therapy
1999
Homoharringtonine: A New Treatment Option for Myeloid Leukemia
2004
Imatinib promotes apoptosis of giant cell tumor cells by targeting microRNA-30a-mediated runt-related transcription factor 2
2015
Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives
2014
Heat Shock Protein A12B Protects Vascular Endothelial Cells Against Sepsis-Induced Acute Lung Injury in Mice
2017 Standout
Cellular and molecular mechanisms of renal fibrosis
2011 Standout
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
2007
Current approach to the treatment of chronic myeloid leukaemia
2017
Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells
2011
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Viruses in human cancers
1999 StandoutNobel
Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells
2012
Revealing the world of RNA interference
2004 StandoutNatureNobel
Artificial Intelligence in Cardiology
2018 Standout
CURCUMIN: THE INDIAN SOLID GOLD
2007 Standout
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Astrocyte–endothelial interactions at the blood–brain barrier
2005 Standout
The blood–brain barrier: an overview
2004 Standout
Multi-Organ, Multi-Lineage Engraftment by a Single Bone Marrow-Derived Stem Cell
2001 Standout
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
2006
Impact of gene-modified T cells on HIV infection dynamics
2005 StandoutNobel
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
2005
Nutritional support for chronic myelogenous and other leukemias: a review of the scientific literature.
2002
Molecular Analysis of Eight Biochemically Unique Glucose-6-Phosphate Dehydrogenase Variants Found in Japan
1997
Induction of Astrocyte Differentiation by Endothelial Cells
2001
Human Parvovirus B19
2002 Standout
Instructive cytokine signals in dendritic cell lineage commitment
2010
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine
1999
Cytokine Activation of Endothelial Cells: New Molecules for an Old Paradigm
1997
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
1999
SGX393 inhibits the CML mutant Bcr-Abl T315I and preempts in vitro resistance when combined with nilotinib or dasatinib
2008
Marine natural products
2018 Standout
The Versatile Role of microRNA-30a in Human Cancer
2017 Standout
Pluripotency and nuclear reprogramming
2008 StandoutNobel
Glucose-6-phosphate dehydrogenase deficiency
2008 Standout
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice
2017
Endothelial cells in physiology and in the pathophysiology of vascular disorders.
1998 Standout
Leukemia-Inhibitory Factor—Neuroimmune Modulator of Endocrine Function*
2000
Possible evolution of human parvovirus B19 infection into erythroleukemia.
1999
Discovery of Novel Antiangiogenic Marine Natural Product Scaffolds
2016
Drug Resistance in Cancer: An Overview
2014 Standout
Endothelial Cell Biology
2010
New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
2006
The Dendritic Cell Lineage: Ontogeny and Function of Dendritic Cells and Their Subsets in the Steady State and the Inflamed Setting
2013 Standout
Chronic Myelogenous Leukemia: Biology and Therapy
1999
Works of F-X Mahon being referenced
First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia
2012
Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells
2009
Rapid analysis and efficient selection of human transduced primitive hematopoietic cells using the humanized S65T green fluorescent protein
1998
Expression of Flt3-ligand by the endothelial cell
2000
All-trans retinoic acid potentiates the inhibitory effects of interferon α on chronic myeloid leukemia progenitors in vitro
1997
Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs
2002
Endothelial cell support of hematopoiesis is differentially altered by IL-1 and glucocorticoids
1998
The stem cell factor–c-KIT pathway must be inhibited to enable apoptosis induced by BCR–ABL inhibitors in chronic myelogenous leukemia cells
2009
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)
2006
In vitro biosynthesis of leukemia inhibitory factor/human interleukin for DA cells by human endothelial cells: differential regulation by interleukin-1 alpha and glucocorticoids
1995
Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon alpha [letter; comment]
1994